GLP Watchdog

Best Weight Loss Supplements in 2026 — Ranked & Reviewed

Value, effectiveness and user experience, among other measures, decide the scores we give the leading weight loss supplements of 2026.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Providers in this category are still being evaluated. Rankings will follow.
How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →
Arrived here looking for “natural Ozempic,” a “GLP-1 supplement,” or the best over-the-counter “natural GLP-1”? Not one OTC supplement is a GLP-1 receptor agonist. The products sold as “natural Ozempic” or “GLP-1 support” — apple cider vinegar, berberine, capsaicin, chromium, soluble fiber — work on unrelated pathways, and pooled they come to roughly 1–2 kg of weight loss. Prescription semaglutide (−14.9%, STEP 1) and tirzepatide (−20.9%, SURMOUNT-1) are roughly 10x stronger. If you want one anyway, the supplement board ranks what is actually sold, with the same scoring we apply everywhere else. It will not turn any of them into a GLP-1.

Frequently Asked Questions

Sources & methodology — as of August 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings